Alfentanil

證據等級: L5

預測適應症: 1 個

Alfentanil: From Anesthesia/Analgesia to Nephrogenic Syndrome of Inappropriate Antidiuresis

One-Sentence Summary

Alfentanil is a short-acting synthetic opioid analgesic used for induction and maintenance of anesthesia and procedural sedation. The TxGNN model predicts it may be effective for Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), however 0 clinical trials and 0 publications currently support this direction — the evidence base is limited to the model prediction alone.

Quick Overview

Item	Content
Original Indication	Anesthesia induction and maintenance; procedural analgesia
Predicted New Indication	Nephrogenic Syndrome of Inappropriate Antidiuresis
TxGNN Prediction Score	99.51%
Evidence Level	L5
Saudi Arabia Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on established pharmacological knowledge, Alfentanil is a potent, ultra–short-acting µ-opioid receptor agonist with a rapid onset (approximately 1–2 minutes) and brief duration of action relative to fentanyl. It is primarily used for intraoperative analgesia, anesthesia induction, and procedural sedation. Its mechanism centres on agonism at central and peripheral µ-opioid receptors, suppressing pain signal transmission through the inhibition of adenylyl cyclase (↓ cAMP) and modulation of ion channels.

Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD) is a rare X-linked disorder caused by gain-of-function mutations in the V2 vasopressin receptor (AVPR2). These mutations result in constitutive receptor activation — elevated cAMP signalling and aquaporin-2 trafficking — leading to inappropriate water reabsorption and dilutional hyponatremia, even in the absence of elevated antidiuretic hormone (ADH). Clinically it resembles SIADH, but with suppressed ADH levels.

A theoretical mechanistic bridge may exist: µ-opioid receptors and V2 vasopressin receptors both signal through the Gαi/Gαs–cAMP axis, and opioid agonists have been reported in some contexts to modulate renal tubular water handling. However, the specific hypothesis that alfentanil could attenuate constitutively active V2R in NSIAD is highly speculative. No clinical trials, observational studies, or literature were identified to support this direction, making the TxGNN prediction unvalidated at this time.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a very high TxGNN prediction score (99.51%), there is a complete absence of clinical or published evidence connecting alfentanil to nephrogenic syndrome of inappropriate antidiuresis, and the drug carries no Saudi Arabia regulatory authorisations, making a forward development case premature.

To proceed, the following is needed:

Mechanistic studies investigating whether µ-opioid receptor agonism modulates constitutively active V2 vasopressin receptor signalling relevant to NSIAD
Retrieval and review of the official package insert for complete safety data (warnings, contraindications, drug–drug interactions)
At minimum one preclinical or observational study demonstrating an effect on V2R-mediated renal water handling
TxGNN model explainability analysis (graph path / feature importance) to understand the basis of this high-confidence prediction
Regulatory pathway scoping for a novel indication in a drug not currently marketed locally
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.